• Explore /
  • Poster
  • / Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

Abstract Poster

Authors

null

James J. Lee

University of Pittsburgh Cancer Institute, Pittsburgh, PA

James J. Lee , John D. Powderly II, Manish R. Patel , Joshua Brody , Erika Paige Hamilton , Jeffrey R. Infante , Gerald Steven Falchook , HongWei Wang , Lisa Adams , Lucy Gong , Anna W Ma , Timothy Wyant , Adam Lazorchak , Shefali Agarwal , Adil Daud , David P. Tuck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02812875

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3099)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3099

Abstract #

TPS3099

Poster Bd #

190a

Abstract Disclosures

Similar Posters

First Author: Timothy A. Yap

First Author: Jiajian Liu

First Author: Jiajian Liu

First Author: Pei Shu